Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NSE India Stock Exchange  >  Cipla Limited    CIPLA   INE059A01026

CIPLA LIMITED

(CIPLA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nse India Stock Exchange
01/12/2021 01/13/2021 01/14/2021 01/15/2021 01/18/2021 Date
843.15(c) 841.7(c) 840.9(c) 823.7(c) 801.75 Last
4 338 010 3 596 529 3 652 930 3 137 877 3 742 440 Volume
-1.60% -0.17% -0.10% -2.05% -2.66% Change
More quotes
Financials
Sales 2021 192 B 2 617 M 2 617 M
Net income 2021 24 111 M 329 M 329 M
Net Debt 2021 3 392 M 46,3 M 46,3 M
P/E ratio 2021 27,7x
Yield 2021 0,47%
Sales 2022 208 B 2 841 M 2 841 M
Net income 2022 26 505 M 362 M 362 M
Net cash position 2022 15 930 M 218 M 218 M
P/E ratio 2022 24,9x
Yield 2022 0,54%
Capitalization 664 B 9 081 M 9 075 M
EV / Sales 2021 3,49x
EV / Sales 2022 3,12x
Nbr of Employees 25 845
Free-Float 61,5%
More Financials
Company
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and... 
Sector
Pharmaceuticals
Calendar
01/29Earnings Release
More about the company
Notations Surperformance© of Cipla Limited
Trading Rating : Investor Rating :
More Ratings
All news about CIPLA LIMITED
2020Indian Indices Witness Strong Buying; Punjab National Bank Drops 6%
MT
2020CIPLA : Partners with Premier Medical Corporation for COVID-19 Rapid Tests
MT
2020BRISTOL MYERS SQUIBB : Announces Settlement of U.S. Patent Litigation for REVLIM..
AQ
2020Sensex, Nifty end higher; Burger King more than doubles in market debut
RE
2020Indian Equities Settle in Green; Larsen & Toubro Up 5%
MT
2020Indian shares end higher; Burger King more than doubles in market debut
RE
2020CIPLA : Settles US Patent Litigation for Revlimid with Bristol Myers Unit; Share..
MT
2020BRISTOL MYERS SQUIBB : Settles REVLIMID Patent Litigation With Cipla
MT
2020BRISTOL MYERS SQUIBB : Says Celgene, Cipla Have Settled Litigation
DJ
2020CIPLA : New Medicines Should Make Life Easier for Kids Living With HIV
AQ
2020CIPLA : University of Cambridge - Department of Chemistry to be named in honour ..
AQ
2020Cipla Signs Licensing Agreement For Multi G's COVID-19 Rapid Antibody Test Ki..
MT
2020Indian Indices Close Higher on Monday; Divi's Laboratories Shares Reach All-T..
MT
2020Indian demand for COVID-19 drug remdesivir rising sharply - Cipla
RE
2020Cipla's Consolidated Net Profit Rises in September Quarter
MT
More news
News in other languages on CIPLA LIMITED
2020CIPLA LIMITED : Veröffentlichung des Halbjahresergebnisses
2020CIPLA LIMITED : publication des résultats semestriels
2020CIPLA LIMITED : Veröffentlichung des Quartalsergebnisses
2020CIPLA LIMITED : publication des résultats trimestriels
2020CIPLA : L'Inde autorise une version générique de l'anti-COVID de Gilead
More news
Chart CIPLA LIMITED
Duration : Period :
Cipla Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CIPLA LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 32
Average target price 916,90 INR
Last Close Price 823,70 INR
Spread / Highest target 26,3%
Spread / Average Target 11,3%
Spread / Lowest Target -12,6%
EPS Revisions
Managers and Directors
NameTitle
Umang Vohra Chief Executive Officer, MD & Director
Raju Mistry President & Global Chief People Officer
Yusuf Khwaja Hamied Non-Executive Chairman
Kedar Upadhye Global Chief Financial Officer
Jaideep A. Gogtay Global Chief Medical Officer
Sector and Competitors